Search clinical trials for: Doxorubicine pegylated

Total 2439 results

French Innovative Leukemia Organisation

Completed

Liposomal Anthracyclin in the Treatment of Elderly ALL

Acute Lymphoblastic Leukemia

France
University of Regensburg
Essex Pharma Germany

Completed

Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma

Germany
Sun Yat-sen University

Unknown

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Ovarian Cancer

China
GlaxoSmithKline

Completed

Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

Neoplasms, Ovarian

United States
SOLTI Breast Cancer Research Group
Schering-Plough

Completed

Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years (CAPRICE)

Breast Cancer

Spain
MedSIR
Roche Pharma AG; Experior

Completed

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (THELMA)

Breast Cancer

France, Spain
Cancer Institute and Hospital, Chinese Academy...
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

HER2-positive Breast Cancer

China
French Innovative Leukemia Organisation

Completed

Treatment of Disseminated High Grade Lymphoma

Lymphoma

France
Fudan University

Recruiting

Metronomic PLD in Patients With Primary Endocrine Resistant ABC

Advanced Breast Cancer

China
National Cancer Institute (NCI)

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...

United States
University of Arizona

Terminated

Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy

Breast Cancer

United States
Spanish Breast Cancer Research Group
Schering-Plough

Completed

Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

Breast Neoplasms

Spain
European Organisation for Research and Treatment...

Completed

Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides

Lymphoma

Germany, Switzerland, Israel, United Kingdom, Austria, Italy
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Patients With Sarcoma of the Uterus

Sarcoma | Endometrial Cancer

United States, Canada
Yong Chen

Unknown

Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma

Stage III Adult Soft Tissue Sarcoma

China
AGC Biologics S.p.A.

Completed

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Ovarian Cancer

Italy
AGC Biologics S.p.A.

Completed

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer (NGR018)

Ovarian Cancer

Italy, United Kingdom
University of Leicester

Unknown

Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer

Gastric Cancer | Esophageal Cancer

United Kingdom
ARCAGY/ GINECO GROUP

Completed

Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer

Breast Cancer

France
European Organisation for Research and Treatment...

Completed

Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Breast Cancer

France, Spain, Netherlands, United Kingdom, Italy, Israel, Switzerland, Greece, Austria
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

Breast Neoplasm
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Ovarian Neoplasms
Tianjin Medical University Second Hospital
CSPC Pharmaceutical Group Limited

Unknown

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Muscle Invasive Bladder Cancer

China
Fudan University

Not yet recruiting

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

Ovarian Cancer
Merck Sharp & Dohme LLC

Terminated

Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)

Breast Neoplasm
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer

Endometrial Cancer

United States
Imunon

Completed

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Brown University

Unknown

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Seoul National University Hospital

Unknown

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

High Grade Serous Carcinoma | Ovarian Neoplasm Epithelial

Korea, Republic of
Swiss Group for Clinical Cancer Research

Completed

F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Breast Cancer | Palmar-plantar Erythrodysesthesia

Switzerland
Merck Sharp & Dohme LLC

Terminated

Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

Breast Neoplasms
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Aprea Therapeutics

Completed

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

High-grade Serous Ovarian Cancer

Spain, United Kingdom, Belgium
Roswell Park Cancer Institute

Terminated

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Endometrial Cancer

United States
The Netherlands Cancer Institute

Unknown

Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases

Meningeal Carcinomatosis

Netherlands
AGO Study Group

Completed

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

Germany
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Withdrawn

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Multiple Myeloma
Georgetown University
National Cancer Institute (NCI)

Completed

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

Unspecified Adult Solid Tumor, Protocol Specific

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Cervical Cancer

United States, Norway
Merck Sharp & Dohme LLC

Completed

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

Ovarian Neoplasms
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Sarcoma | Unspecified Adult Solid Tumor, Protocol Specific

United States
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Breast Cancer

Greece
Millennium Pharmaceuticals, Inc.

Withdrawn

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Ovarian Cancer

Italy, Switzerland
Celgene
Gynecologic Oncology Group

Completed

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Merck Sharp & Dohme LLC
Princess Margaret Hospital, Canada

Completed

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Ovarian Neoplasms
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States

3

Subscribe